RPTX
Repare Therapeutics Inc.Company Information
- Company Name
- Repare Therapeutics Inc.
- CIK
- CIK0001808158
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- RPTX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- RPTX
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-11-16
- Last sale
- 2025-03-12
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 45,685
Institutional Sentiment
- As of
- 2025-12-31
- Institutional shares owned
- 24,438,387
- Shares outstanding
- 42,965,529
- Ownership
- 56.88%
Earnings Market Reaction
- Filing date
- 2025-11-14
- Price on filing date
- —
- 1-month reaction
- 34.24%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 73 | 68 | 84 | 85 | 81 | 80 | 103 | 111 | 107 | 116 | 121 | 160 | ||||||
| Marketable Securities Current | 40 | 42 | 40 | 68 | 99 | 128 | 134 | 112 | 143 | 165 | 193 | 184 | ||||||
| Receivables Long Term Contracts Or Programs | - | - | - | - | - | - | - | - | - | - | 4 | 2 | ||||||
| Other Receivables | - | - | - | - | - | - | - | - | - | - | 1 | 2 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 124 | 127 | 140 | 171 | 200 | 229 | 255 | 244 | 275 | 292 | 326 | 354 | ||||||
| Income Tax Receivable | - | - | - | - | - | - | - | - | - | 2 | - | - | ||||||
| Income Taxes Receivable | 2 | 10 | 10 | 11 | 11 | 11 | 11 | 11 | 16 | - | - | 0 | ||||||
| Other Receivables Net Current | 6 | 5 | 2 | 2 | 3 | 4 | 3 | 4 | 4 | 5 | - | 4 | ||||||
| Prepaid Expense Current | 4 | 2 | 5 | 6 | 7 | 6 | 3 | 5 | 6 | 4 | 4 | 6 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 1 | 2 | 3 | 3 | 4 | 4 | 5 | 5 | 5 | 4 | ||||||
| Operating Lease Right Of Use Asset | 0 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 4 | 4 | 5 | 5 | ||||||
| Income Taxes Receivable Noncurrent | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | - | - | 0 | ||||||
| Equity Securities Without Readily Determinable Fair Value Amount | 2 | 2 | - | - | - | - | - | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Income Tax Assets Net | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Assets | 127 | 130 | 144 | 177 | 206 | 235 | 263 | 254 | 286 | 302 | 336 | 364 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 1 | 4 | 2 | 4 | 11 | 7 | 7 | 2 | 5 | 5 | 4 | 0 | ||||||
| Accrued Liabilities And Other Liabilities | 10 | 12 | 15 | 20 | 18 | 22 | 20 | 24 | 21 | 22 | 17 | 22 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 12 | 20 | 19 | 25 | 31 | 31 | 31 | 39 | 49 | 53 | 81 | 79 | ||||||
| Operating Lease Liability Current | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Contract With Customer Liability Current | - | - | - | 0 | 0 | 0 | 1 | 10 | 20 | 24 | 53 | 53 | ||||||
| Accrued Income Taxes Current | - | - | - | - | - | - | - | 0 | 0 | 0 | 5 | 1 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 3 | 3 | ||||||
| Contract With Customer Liability Noncurrent | - | - | - | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 1 | 3 | ||||||
| Liabilities | 12 | 20 | 19 | 25 | 31 | 32 | 31 | 42 | 53 | 56 | 85 | 85 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 490 | 490 | 490 | 487 | 487 | 486 | 486 | 483 | 483 | 483 | 483 | 482 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 115 | 110 | 125 | 151 | 175 | 204 | 232 | 212 | 233 | 245 | 251 | 280 | ||||||
| Warrants And Rights Outstanding | 0 | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | ||||||
| Additional Paid In Capital Common Stock | 86 | 85 | 83 | 82 | 77 | 72 | 66 | 62 | 56 | 49 | 43 | 37 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -461 | -465 | -448 | -418 | -389 | -355 | -320 | -333 | -305 | -286 | -274 | -239 | ||||||
| Liabilities And Stockholders Equity | 127 | 130 | 144 | 177 | 206 | 235 | 263 | 254 | 286 | 302 | 336 | 364 | ||||||
| Preferred Stock No Par Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock No Par Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Shares Issued | 43 | 43 | 43 | 43 | 43 | 42 | 42 | 42 | 42 | 42 | 42 | 42 | ||||||
| Shares Outstanding | 43 | 43 | 43 | 43 | 43 | 42 | 42 | 42 | 42 | 42 | 42 | 42 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialRepare Therapeutics Inc. (RPTX) — SEC Financial Statements & Analysis
Repare Therapeutics Inc. (RPTX) is a pharmaceutical preparations company, incorporated in Z4. Repare Therapeutics Inc. trades on Nasdaq as: RPTX. Repare Therapeutics Inc. (RPTX)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-14. Based on that filing, On profitability, Repare Therapeutics Inc. posts a Return on Equity (ROE) of -49.78%, a Return on Assets (ROA) of -43.35%, and a Return on Invested Capital (ROIC) of -114.05%. Per share, it reports EPS of $-1.68, diluted EPS of $-1.68, free cash flow per share of $-1.63, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -14.10% year-over-year and EPS growth of -15.12% year-over-year. On the balance sheet, it maintains a current ratio of 10.71x, a quick ratio of 10.40x, working capital of $112.81M, a debt-to-equity ratio of 0.10x, a debt ratio of 0.09, free cash flow of $-70.15M (TTM), and net debt of $-72.83M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-1.68
- ROE TTM
- -49.78%
- ROA TTM
- -43.35%
- Debt To Equity
- 0.10x
- Free Cash Flow TTM
- $-70.15M
Data as of 2025-09-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Repare Therapeutics Inc. in?
Repare Therapeutics Inc. (RPTX) operates in the Pharmaceutical Preparations industry.
What exchange does RPTX trade on?
Repare Therapeutics Inc. (RPTX) trades on the Nasdaq.
Where is Repare Therapeutics Inc. incorporated?
Repare Therapeutics Inc. is incorporated in Canada (Federal Level).
When was Repare Therapeutics Inc. (RPTX)'s most recent SEC filing?
Repare Therapeutics Inc. (RPTX)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-14.
What is RPTX's EPS (earnings per share)?
Repare Therapeutics Inc. (RPTX)'s trailing twelve month EPS is $-1.68 as of 2025-09-30.
What is RPTX's ROE (return on equity)?
Repare Therapeutics Inc. (RPTX)'s trailing twelve month Return on Equity (ROE) is -49.78% as of 2025-09-30.
What is RPTX's ROA (return on assets)?
Repare Therapeutics Inc. (RPTX)'s trailing twelve month Return on Assets (ROA) is -43.35% as of 2025-09-30.
What is RPTX's ROIC (return on invested capital)?
Repare Therapeutics Inc. (RPTX)'s trailing twelve month Return on Invested Capital (ROIC) is -114.05% as of 2025-09-30.